Minimal Residual Disease Eradication in CML: Does It Really Matter?

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Tyrosine kinase inhibitors (TKIs) have significantly improved outcomes for chronic phase chronic myeloid leukemia (CP-CML).
• Patient survival in CP-CML is now primarily influenced by non-leukemia related mortality.
• Monitoring minimal residual disease via BCR-ABL1 mRNA levels is crucial for CML management.

Purpose of the Study:

• To discuss the emerging clinical practice of discontinuing TKIs in CP-CML patients.
• To highlight the requirements for successful TKI discontinuation and treatment-free remission (TFR).
• To review strategies aimed at eliminating CML stem cells for broader TFR eligibility.

Main Methods:

• Review of current clinical practices and trial data regarding TKI discontinuation.
• Analysis of molecular monitoring techniques for residual disease.
• Exploration of preclinical therapeutic strategies for CML stem cell eradication.

Main Results:

• A stable deep molecular response offers approximately 50% chance of achieving TFR after TKI cessation.
• TKI discontinuation, while moving towards clinical practice, is currently mainly within clinical trials.
• Despite preclinical promise, no new strategies to eliminate CML stem cells have entered clinical practice.

Conclusions:

• Successful TKI discontinuation requires careful patient selection, intensive molecular monitoring, and prompt treatment re-initiation upon relapse.
• Achieving TFR in more CP-CML patients remains an active area of research, with a focus on eradicating CML stem cells.
• While TFR is becoming more accessible, further therapeutic advancements are needed to benefit a wider patient population.